Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
FATE
#3409
Fate Therapeutics, Inc. - Common Stock
2.0
0
USD
-0.06%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-6.10%
Monthly Change
-13.04%
6 month change
+49.25%
Year Change
+44.93%
Previous Close
2.1
3
Open
2.1
3
Low
1.9
8
High
2.1
3
Markets
US Stock Market
Healthcare
Biotechnology
FATE
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
2013
Quarterly report, Q3 FY2013
2013.11.13
FATE THERAPEUTICS INC quarterly report, Q3 FY2013
10-Q
1
2
3
4
5
6
7
8
News
Fate Therapeutics Receives $15M CIRM Grant To Advance Phase 2 FT819 Trial In Lupus Nephritis
Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead (NASDAQ:FATE)
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates
Macro Note: The Tech Unwind Grew A Second Leg, And It’s Healthcare
Fate Therapeutics’s FT819 Progress Keeps My Bull Case Alive (NASDAQ:FATE)
Wall Street Lunch: BP Slips After Ousting Chairman Albert Manifold Over Governance Concern
5 Healthcare Stocks Set to Join the Russell 3000 - TipRanks.com
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Novavax (NVAX) Reports Q1 Loss, Beats Revenue Estimates
Fate Therapeutics at Leerink Global Healthcare Conference: Strategic Shift in Focus